AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34255051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost conversations
Number of subjects: 830
Study 33115541 — intervention group
Group type: COMPARATOR
Intervention: Protocols approved in 2012
Number of subjects: 852
Study 33115541 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols approved in 2016
Number of subjects: 852
Study 34656207 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (direct-to-injection group)
Number of subjects: 283
Study 34656207 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (oral lead-in group)
Number of subjects: 283
Study 34656207 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine (randomly assigned long-acting group)
Number of subjects: 283
Study 34656207 — intervention group
Group type: COMPARATOR
Intervention: Standard of care oral regimen (control group)
Number of subjects: 283
Study 34656207 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site reactions (adverse events)
Number of subjects: 283
Study 34656207 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal due to adverse events
Number of subjects: 283
Study 32698159 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens and bazedoxifene (CE/BZA)
Number of subjects: 8
Study 33491604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritualized chanting with palliative care (RCPC)
Number of subjects: 60
Study 33491604 — intervention group
Group type: COMPARATOR
Intervention: Palliative care alone (PCA)
Number of subjects: 60
Study 32460712 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose regimen of Mebendazole (100 mg twice a day for three consecutive days)
Number of subjects: 108
Study 32460712 — intervention group
Group type: COMPARATOR
Intervention: Single dose regimen of Mebendazole (500 mg)
Number of subjects: 108
Study 35793178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) plus Dexamethasone (5 mg in 1 mL)
Number of subjects: 103
Study 35793178 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Radiofrequency (PRF) plus Normal Saline (1 mL)
Number of subjects: 103
Study 34216862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (32 mg total IV over 270 min)
Number of subjects: 8
Study 34216862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four doses IV)
Number of subjects: 8
Study 32845312 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit‐lesion‐only percutaneous coronary intervention with optional staged revascularization
Number of subjects: 685
Study 32845312 — intervention group
Group type: COMPARATOR
Intervention: Immediate multivessel percutaneous coronary intervention
Number of subjects: 685
Study 33423392 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity exercise program (2 times per week plus additional personal choice session)
Number of subjects: 100
Study 33423392 — intervention group
Group type: COMPARATOR
Intervention: Standard care and instructions to maintain physical activity level (Control)
Number of subjects: 100
Study 35431960 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM formula (BHT, Bushen Huoxue Tongluo) and informative counseling
Number of subjects: 24
Study 35431960 — intervention group
Group type: COMPARATOR
Intervention: Informative counseling alone
Number of subjects: 24
Study 32627271 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg daily
Number of subjects: 241
Study 32627271 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 241
Study 32777142 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 20
Study 32942789 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation on the genicular nerve (RFTGN)
Number of subjects: 0
Study 32942789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular pulsed radiofrequency (IAPRF)
Number of subjects: 0
Study 32942789 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular steroid injection (IAS)
Number of subjects: 0
Study 35230504 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable suture (Monocryl®, Ethicon Inc.)
Number of subjects: 114
Study 35230504 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable suture (Prolene®, Ethicon Inc.)
Number of subjects: 114
Study 35230504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Absorbable and Non-absorbable sutures)
Number of subjects: 114
Study 32990882 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum HrQoL measures
Number of subjects: 171
Study 32990882 — intervention group
Group type: COMPARATOR
Intervention: Minimum HrQoL measures plus psychosocial outcomes
Number of subjects: 171
Study 35416190 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA group (calorie-restricted diet -700 kcal d-1 + HCA tablets)
Number of subjects: 40
Study 35416190 — intervention group
Group type: COMPARATOR
Intervention: Control group (calorie-restricted diet only)
Number of subjects: 40
Study 35416190 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA group
Number of subjects: 40
Study 35416190 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 34268624 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rectus sheath block (CRSB)
Number of subjects: 100
Study 34268624 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anesthesia (CEA)
Number of subjects: 100
Study 36154972 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery work
Number of subjects: 25
Study 36154972 — intervention group
Group type: EXPERIMENTAL
Intervention: All works (breathing, stretching, imagery)
Number of subjects: 25
Study 36154972 — intervention group
Group type: COMPARATOR
Intervention: Breathing
Number of subjects: 25
Study 36154972 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 25
Study 36154972 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 34156161 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg baicalein tablet
Number of subjects: 36
Study 34156161 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg baicalein tablet
Number of subjects: 36
Study 34156161 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg baicalein tablet
Number of subjects: 36
Study 34156161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32457513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based educational intervention
Number of subjects: 70
Study 36434669 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage with chamomile oil
Number of subjects: 154
Study 36434669 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage without chamomile oil
Number of subjects: 154
Study 36434669 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine labor care)
Number of subjects: 154
Study 34749822 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT) intervention, 12 weeks, bicycle-based, delivered twice weekly in a face-to-face, one-to-one setting.
Number of subjects: 40
Study 34749822 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT) intervention, naturalistic study, two sessions of HIIT per week, delivered remotely or in person.
Number of subjects: 40
Study 34749822 — intervention group
Group type: COMPARATOR
Intervention: Self-directed HIIT sessions using the bike.
Number of subjects: 40
Study 34749822 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study 33126902 — intervention group
Group type: EXPERIMENTAL
Intervention: Active expiratory muscle FES
Number of subjects: 20
Study 33126902 — intervention group
Group type: COMPARATOR
Intervention: Sham expiratory muscle FES
Number of subjects: 20
Study 35673263 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one coaching sessions plus access to the MS INFoRm website
Number of subjects: 26
Study 35673263 — intervention group
Group type: COMPARATOR
Intervention: Two check-in phone calls plus access to the MS INFoRm website
Number of subjects: 26
Study 32024747 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational learning dimensions (systems thinking, team learning, shared vision)
Number of subjects: 150
Study 34542612 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 222
Study 34542612 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 222
Study 34542612 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 222
Study 34542612 — intervention group
Group type: COMPARATOR
Intervention: ICA
Number of subjects: 222
Study 33205852 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (TPTNS) treatment for 12 weeks
Number of subjects: 44
Study 33205852 — intervention group
Group type: COMPARATOR
Intervention: Sham TPTNS (no current) for 12 weeks
Number of subjects: 44
Study 35233694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin A topical nanoemulsion (Cyporin N®; Taejoon Pharm) twice daily, 0.15% hyaluronic acid eye drops four times daily, and warm compress twice daily for 10 min
Number of subjects: 51
Study 35233694 — intervention group
Group type: COMPARATOR
Intervention: 0.15% hyaluronic acid eye drops six times daily and warm compress twice daily for 10 min
Number of subjects: 51
Study 32472283 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 0% DRC
Number of subjects: 1100
Study 32472283 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 2.5% DRC
Number of subjects: 1100
Study 32472283 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 5.0% DRC
Number of subjects: 1100
Study 32472283 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 7.5% DRC
Number of subjects: 1100
Study 32472283 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 10.0% DRC
Number of subjects: 1100
Study 32472283 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with varying DRC levels
Number of subjects: 1100
Study 32472283 — intervention group
Group type: COMPARATOR
Intervention: Varying DRC levels (0-10%) without enzyme addition
Number of subjects: 1100
Study 34670945 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCC with anterior vitrectomy (group A, n = 26)
Number of subjects: 41
Study 34670945 — intervention group
Group type: COMPARATOR
Intervention: PCCC without anterior vitrectomy (optic capture buttonholing, group B, n = 30)
Number of subjects: 41
Study 34670945 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean spherical equivalent in group A
Number of subjects: 41
Study 34670945 — intervention group
Group type: COMPARATOR
Intervention: Mean spherical equivalent in group B
Number of subjects: 41
Study 32341703 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 34
Study 32833133 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHL)
Number of subjects: 90
Study 32833133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hyaluronic acid (HA)
Number of subjects: 90
Study 32833133 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 33158841 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine prophylaxis
Number of subjects: 0
Study 33158841 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34117181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Number of subjects: 68
Study 34117181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor
Number of subjects: 68
Study 34117181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel (NPR group)
Number of subjects: 68
Study 34117181 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + Ticagrelor (HPR group)
Number of subjects: 68
Study 32147464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaveric simulation training
Number of subjects: 11
Study 32147464 — intervention group
Group type: COMPARATOR
Intervention: Standard 'on the job' training
Number of subjects: 11
Study 36409686 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload (FEOL) training at high intensity (0.075 kg∙m2)
Number of subjects: 12
Study 36409686 — intervention group
Group type: COMPARATOR
Intervention: Barbell half squat (BHS) training at high intensity (80% 1RM)
Number of subjects: 12
Study 36409686 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload (FEOL) training at low intensity (0.015 kg∙m2)
Number of subjects: 12
Study 36409686 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload (FEOL) training at medium intensity (0.035 kg∙m2)
Number of subjects: 12
Study 36409686 — intervention group
Group type: COMPARATOR
Intervention: Barbell half squat (BHS) training at low intensity (40% 1RM)
Number of subjects: 12
Study 36409686 — intervention group
Group type: COMPARATOR
Intervention: Barbell half squat (BHS) training at medium intensity (60% 1RM)
Number of subjects: 12
Study 34756178 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 blockade (anakinra 100 mg subcutaneously once daily for 28 days)
Number of subjects: 342
Study 34756178 — intervention group
Group type: COMPARATOR
Intervention: No IL-1 blockade
Number of subjects: 342
Study 34756178 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 blockade (siltuximab 11 mg/kg or tocilizumab 8 mg/kg intravenously)
Number of subjects: 342
Study 34756178 — intervention group
Group type: COMPARATOR
Intervention: No IL-6 blockade
Number of subjects: 342
Study 34756178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IL-1 and IL-6 blockade
Number of subjects: 342
Study 34756178 — intervention group
Group type: COMPARATOR
Intervention: Both no IL-1 and no IL-6 blockade
Number of subjects: 342
Study 34756178 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 blockade and IL-6 blockade
Number of subjects: 342
Study 34756178 — intervention group
Group type: COMPARATOR
Intervention: No IL-1 blockade and no IL-6 blockade
Number of subjects: 342
Study 36375411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Childbirth and Parenting (MBCP)
Number of subjects: 261
Study 36375411 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care-as-Usual (ECAU)
Number of subjects: 261
Study 35667401 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 42
Study 35667401 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 42
Study 32687924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 (LPHEAL9) for four weeks
Number of subjects: 70
Study 32687924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36387033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light therapy (n = 13)
Number of subjects: 26
Study 36387033 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (sham-intervention; n = 13)
Number of subjects: 26
Study 33119892 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and calorie restriction (PCR) with irinotecan
Number of subjects: 0
Study 33119892 — intervention group
Group type: COMPARATOR
Intervention: Normal diet with irinotecan
Number of subjects: 0
Study 35307291 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 2416
Study 35307291 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 2416
Study 35672761 — intervention group
Group type: EXPERIMENTAL
Intervention: APNEC (acute prehabilitative neuromuscular exercise-conditioning)
Number of subjects: 29
Study 35672761 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 29
Study 32878814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel at a dose of 25 mg/m2 (on day 1 of each 3-week cycle)
Number of subjects: 26
Study 32878814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 26
Study 36455805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise (cycling)
Number of subjects: 52
Study 36455805 — intervention group
Group type: COMPARATOR
Intervention: Control (stretching)
Number of subjects: 52
Study 33624333 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical correlation analysis (CCA) with varying subject-to-variable ratios (SVR) and correlation strengths
Number of subjects: 936
Study 33624333 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent data set (n = 700) for validation
Number of subjects: 936
Study 32595189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved group
Number of subjects: 66
Study 32595189 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 32407170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nostalgia-inducing PSA
Number of subjects: 148
Study 32407170 — intervention group
Group type: COMPARATOR
Intervention: Control PSA (without nostalgia)
Number of subjects: 148
Study 33617679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, twice daily)
Number of subjects: 60
Study 33617679 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care regimen (Control)
Number of subjects: 60
Study 33788450 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at LI4, 2 Hz, 0.5 to 1 mA, 30 min
Number of subjects: 10
Study 33788450 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (placebo needle, no skin penetration)
Number of subjects: 10
Study 36316861 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Granules combined with Western medicine
Number of subjects: 0
Study 36316861 — intervention group
Group type: COMPARATOR
Intervention: Xuefu Zhuyu Granules mimic (placebo) combined with Western medicine
Number of subjects: 0
Study 33191263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab (200 mg and 400 mg) plus best available therapy (BAT)
Number of subjects: 120
Study 33191263 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy (BAT)
Number of subjects: 120
Study 33908053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 898
Study 32404035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg or 150 mg twice daily
Number of subjects: 5390
Study 32404035 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 5390
Study 35379306 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Brazilian green propolis extract (900 mg/day) for 10 days
Number of subjects: 100
Study 35379306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34133205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose gadobutrol (0.075 mmol/kg)
Number of subjects: 141
Study 34133205 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose gadoterate (0.1 mmol/kg)
Number of subjects: 141
Study 34133205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose gadobutrol
Number of subjects: 141
Study 34133205 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose gadoterate
Number of subjects: 141
Study 32843703 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of naltrexone
Number of subjects: 20
Study 32843703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33906052 — intervention group
Group type: EXPERIMENTAL
Intervention: TEXT-WMN
Number of subjects: 2
Study 33906052 — intervention group
Group type: COMPARATOR
Intervention: VOICE-TWR
Number of subjects: 2
Study 32243036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 9795
Study 32243036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study 36204923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ride-on electric cars (ride-on e-cars)
Number of subjects: 115
Study 36204923 — intervention group
Group type: COMPARATOR
Intervention: Trolley transport (control)
Number of subjects: 115
Study 33273438 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticosteroid in the retropharyngeal space
Number of subjects: 109
Study 33273438 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroid)
Number of subjects: 109
Study 36072907 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianyao Migu granules (JYMGG)
Number of subjects: 108
Study 36072907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 34319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Gojjam Lymphoedema Best Practice Trial (GoLBeT)
Number of subjects: 0
Study 34319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with local community and stakeholders
Number of subjects: 0
Study 34319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research methods
Number of subjects: 0
Study 34319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Study design and planning
Number of subjects: 0
Study 34319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment and training of staff
Number of subjects: 0
Study 34319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Data quality planning
Number of subjects: 0
Study 34319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory approvals
Number of subjects: 0
Study 35534374 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (cardiac myosin stimulator)
Number of subjects: 0
Study 35534374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten (inhibitor for hypertrophic cardiomyopathy)
Number of subjects: 0
Study 35534374 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten (inhibitor for hypertrophic cardiomyopathy)
Number of subjects: 0
Study 32556870 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y (URY)
Number of subjects: 124
Study 32556870 — intervention group
Group type: COMPARATOR
Intervention: Billroth II combined Braun (BB)
Number of subjects: 124
Study 35566530 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) group, n = 18, 10 weeks of lower limb resistance training with a concentric phase at maximum velocity
Number of subjects: 30
Study 35566530 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 12
Number of subjects: 30